Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants - (BMJ)
    Topical Cream Effective Against Cetuximab-Induced Acne-Like Rash: Presented at ESMO-GI - (DGDispatch)
    Endocrine Society Responds to Insulin Glargine Studies With Recommendations - (DGNews)
    Two Bevacizumab-Based Combination Regimens Equally Effective in Patients With Metastatic Colorectal Cancer: Presented at ESMO-GI - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Biologics in Crohn's Disease: Treating Early, Treating Long-Term
    • Urinalysis: A Guide for Pharmacists
      Clinical Management of Nutrition in Hospitalized Patients: Improving Safety and Patient Outcomes
      Advances in the Management of Postoperative Ileus: Reducing the Clinical and Economic Burden
      The Challenge of Type 2 Diabetes: Emerging Options for Improving Glycemic Control

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
        Acute Abdominal Pain in a Patient Receiving Enoxaparin
        Fatal Pneumonitis After Treatment with Docetaxel and Trastuzumab
        Cardiogenic Shock Caused by Disulfiram
        Clopidogrel Resistance "Live" - The Risk of Stent Thrombosis Should Be Evaluated Before Procedures

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Pasireotide Suppresses Growth Hormone in Active Acromegalics: Presented at ACCP

        By Maria Bishop

        BOSTON, MA -- September 18, 2006 -- The relationship between pasireotide and growth hormone (GH) is characterized by a direct, concentration-related effect in active acromegalics, according to investigators presenting here at the American College of Clinical Pharmacology 35th Annual Meeting (ACCP).

        Acromegaly is a rare, serious hormonal disorder characterized by chronic hypersecretion of GH. In this study, 59 patients with active acromegaly due to a pituitary tumor were statistically analyzed for their responses to pasireotide, a novel somatostatin analogue with multiligand properties.

        The study administered 4 weeks of octreotide (100 mcg sc 3 times daily) followed by a randomized, 3-period crossover phase of low, medium and high doses of pasireotide for 4 weeks (200 mcg sc twice daily, 400 mcg sc twice daily and 600 mcg sc twice daily, respectively).

        Of the 59 patients analyzed, 23 (39%) were considered to be clinical responders, said lead investigator Lucy Lee, PharmD, clinical pharmacologist, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, in a presentation on September 17th. The other 36 (61%) patients showed decreased levels of growth hormone and/or insulin-like growth-factor 1 (IGF-1).

        In responders to this study, the median effective pasireotide concentration was 4.6 ng/mL, and the median growth hormone level was 1.46 ng/mL. Responders maintained a lower level of total IGF-1 and free IGF-1, although a dose-response relationship was not apparent there.

        A median growth hormone suppression of at least 70% was achieved in both responders and nonresponders, noted Dr. Lee, a finding that suggests pharmacological activity in even the more resistant subjects within the study population.

        The researchers concluded that a dose of at least 600 mcg twice daily will achieve a mean pasireotide exposure above the median effective concentration. Phase 3 studies will further evaluate clinical response in acromegalic patients starting at doses of 600 mcg twice daily and higher, they added.


        [Presentation title: The Pharmacokinetic-Pharmacodynamic (PK-PD) Relationship of Pasireotide (SOM230), a Novel Somatostatin Analogue, in Patients With Acromegaly. Abstract 107]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send